Recent technological advances in oral drug delivery – a review

Sastry, Srikonda; Nyshadham, Janaki Ram; Fix, Joseph A.

doi:10.1016/s1461-5347(00)00247-9

Cited by 508 publications

(295 citation statements)

References 11 publications

Supporting

Mentioning

285

Contrasting

Unclassified

Order By: Relevance

“…At this early experimental stage, a dye was added by micropipette to represent addition of the model 'drug' for timed release. As noted in an early review (Sastry et al 2000), the binder can be an active or passive medium, with the inclusion of a polymer or drug also influencing decisions as to the phase change behaviour: rapid to avoid particle rearrangement, or slow to enable better matrix binding by solubility. Katstra et al 2000 examined in more detail the translation of the 3DP process to oral dose (tablet) fabrication.…”

Section: D Printing (3dp)mentioning

confidence: 99%

Inkjet printing for pharmaceutics – A review of research and manufacturing

Daly

Harrington

Martin

et al. 2015

International Journal of Pharmaceutics

274

185

View full text Add to dashboard Cite

Abstract:Global regulatory, manufacturing and consumer trends are driving a need for change in current pharmaceutical sector business models, with a specific focus on the inherently expensive research costs, high-risk capital-intensive scale-up and the traditional centralised batch manufacturing paradigm. New technologies, such as inkjet printing, are being explored to radically transform pharmaceutical production processing and the end-to-end supply chain. This review provides a brief summary of inkjet printing technologies and their current applications in manufacturing before examining the business context driving the exploration of inkjet printing in the pharmaceutical sector. We then examine the trends reported in the literature for pharmaceutical printing, followed by the scientific considerations and challenges facing the adoption of this technology. We demonstrate that research activities are highly diverse, targeting a broad range of pharmaceutical types and printing systems. To mitigate this complexity we show that by categorising findings in terms of targeted business models and Active Pharmaceutical Ingredient (API) chemistry we have a more coherent approach to comparing research findings and can drive efficient translation of a chosen drug to inkjet manufacturing.

show abstract

Section: D Printing (3dp)mentioning

confidence: 99%

Inkjet printing for pharmaceutics – A review of research and manufacturing

Daly

Harrington

Martin

et al. 2015

International Journal of Pharmaceutics

274

185

View full text Add to dashboard Cite

show abstract

“…Bulk density [1][2][3][4] Ten gram of powder mixtures was placed into 100ml measuring cylinder and volume noted. The bulk density was calculated by following equation.…”

Section: Pre-compression Evaluation Parametermentioning

confidence: 99%

“…Tapped density [1][2][3][4] The sample powder was placed into 100 ml measuring cylinder. The cylinder was then subjected to a fixed number of taps (100).…”

Section: Bulk Density = Weight Of Powder Bulk Volumementioning

confidence: 99%

“…Carr's index [1][2][3][4] It is one of the most important parameter to characteristic the nature of powders and granules. It can be calculated from the following equation and category of carr's index given in Table 2.…”

Section: Tapped Density = Weight Of Powder Tapped Volumementioning

confidence: 99%

“…Tablets are the most favoured oral solid dosage form mainly because of several advantages like, ease of administration, good chemical and microbiological stability, easy to swallowing, lowest cost among all other solid dosage form, dose precision and least content variability, ease of packing, self-medication, patient compliance. [1][2][3][4] DOI: http://dx.doi.org/10.26510/2394-0859.pbe.2017. 25 …”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Formulation and evaluation of orodispersible tablet of ivabradine hydrochloride

Patel¹,

Patel²,

Bharadia³

2017

PBE

View full text Add to dashboard Cite

Objective: The objective of present research work was to develop formulation of orodispersible tablets of Ivabradine HCl and evaluate it for different evaluation parameters. Methods:The tablets were prepared by direct compression method. The formulation of the tablets were evaluated before compression for characterization of flow properties and after compression for different parameters of orodispersible tablet formulation.Results: Ivabradine hydrochloride orodispersible tablets were developed with considerable increase in drug release as compared to marketed formulations; nine formulations were developed and studied. The difference in drug release values was found to be 100.88 ± 0.10 respectively. The drug was characterized according to different compendial methods, on the basis of identification by HPLC, pH, organoleptic properties and other tests. Parameters evaluated were within prescribed limits and indicated good free flowing properties. The F6 batch with disintegration time 21 ± 3.0 and dissolution 99.29% was selected as optimized formulation. This was compared with conventional marketed formulation and was found superior. Batch F6 was also subjected to stability studies for two months and was tested for its hardness, wetting time, disintegration time, drug contents and dissolution behaviour monthly. Conclusions:By appropriate selection of excipients, it was possible to develop orodispersible tablets of Ivabradine HCl.

show abstract